TGF-β inhibitors for the treatment of cancer

被引：64
|
作者：
Lahn, M [1 ]
Kloeker, S [1 ]
Berry, BS [1 ]
机构：
[1] Eli Lilly & Co, Lilly Corp Ctr, Lilly Res Labs, Therapeut Area Oncol, Indianapolis, IN 46285 USA
来源：
EXPERT OPINION ON INVESTIGATIONAL DRUGS | 2005年 / 14卷 / 06期
关键词：
antisense oligonucleotide; cancer; clinical Studies; knockout mice; monoclonal antibodies; TGF-beta; TGF-beta RI kinase inhibitors;
D O I：
10.1517/13543784.14.6.629
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Advances in understanding the role of transforming growth factor (TGF)-beta in tumorigenesis have led to the development of TGF-beta inhibitors for cancer treatment. Three platforms of TGF-beta inhibitors have evolved: antisense oligonucleotides, monoclonal antibodies and small molecules. in this review, the current stage of development of each known TGF-beta inhibitor will be discussed. As part of the risk/benefit assessment of TGF-beta inhibitors, the known effects of TGF-beta deficiency in mice, non-clinical toxicology studies with TGF-beta inhibitors in rats, and the clinical studies with monoclonal antibodies against TGF-beta will be summarised.
引用
收藏
页码：629 / 641
页数：13
相关论文
共 50 条
  • [21] Identification of Inhibitors of Thrombospondin 1 Activation of TGF-β
    Suto, Mark J.
    Gupta, Vandana
    Mathew, Bini
    Zhang, Wei
    Pallero, Manuel A.
    Murphy-Ullrich, Joanne E.
    ACS MEDICINAL CHEMISTRY LETTERS, 2020, 11 (06): : 1130 - 1136
  • [22] TGF- Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma
    Alvarez, Marcus A.
    Freitas, Julia Pedo
    Hussain, S. Mazher
    Glazer, Evan S.
    JOURNAL OF GASTROINTESTINAL CANCER, 2019, 50 (02) : 207 - 213
  • [23] TGF-β Inhibitors in Metastatic Pancreatic Ductal Adenocarcinoma
    Marcus A. Alvarez
    Júlia Pedó Freitas
    S. Mazher Hussain
    Evan S. Glazer
    Journal of Gastrointestinal Cancer, 2019, 50 : 207 - 213
  • [24] Inhibitors/antagonists of TGF-β system in kidney fibrosis
    Yanagita, Motoko
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (10) : 3686 - 3691
  • [25] From TGF-β to cancer therapy
    Huang, XM
    Lee, C
    CURRENT DRUG TARGETS, 2003, 4 (03) : 243 - 250
  • [26] TGF-β Inhibitors for Therapeutic Management of Kidney Fibrosis
    Park, Cheol Ho
    Yoo, Tae-Hyun
    PHARMACEUTICALS, 2022, 15 (12)
  • [27] TGF-β signaling in cancer metastasis
    Xie, Feng
    Ling, Li
    van Dam, Hans
    Zhou, Fangfang
    Zhang, Long
    ACTA BIOCHIMICA ET BIOPHYSICA SINICA, 2018, 50 (01) : 121 - 132
  • [28] Targeting TGF-β signaling in cancer
    Katz, Lior H.
    Li, Ying
    Chen, Jiun-Sheng
    Munoz, Nina M.
    Majumdar, Avijit
    Chen, Jian
    Mishra, Lopa
    EXPERT OPINION ON THERAPEUTIC TARGETS, 2013, 17 (07) : 743 - 760
  • [29] TGF-β signaling in progression of cancer
    Miyazono, Kohei
    CANCER SCIENCE, 2021, 112 : 130 - 130
  • [30] Basics of TGF-β and pancreatic cancer
    Truty, Mark J.
    Urrutia, Raul
    PANCREATOLOGY, 2007, 7 (5-6) : 423 - 435
12345